IceCure Medical Ltd. Reports 42% Surge in ProSense® Sales - January 2025 Insights

Here are the key insights extracted from the provided financial report section:

1. Company Identification:

• Name: IceCure Medical Ltd.
• Address: 7 Ha’Eshel St., PO Box 3163, Caesarea, 3079504 Israel.
• SEC File Number: 001-40753.

2. Report Details:

• Form Type: Form 6-K, which is used for foreign private issuers to report certain significant events.
• Report Month: January 2025 (Report No. 3).

3. Press Release Highlight:

• On January 13, 2025, the company issued a press release titled “IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense® Sales for 2024 in North America.”
• This indicates a significant growth in the sales of their ProSense product, suggesting positive business performance and possibly strong market demand.

4. Exhibits and Registrations:

• The press release is included as Exhibit 99.1 and is incorporated into the company's Registration Statements on Form F-3 and Form S-8 with various registration numbers provided.
• This incorporation suggests that the information in the press release is material and relevant for investors and must be disclosed in filings with the SEC.

5. Management Signatory:

• The report is signed by Eyal Shamir, the Chief Executive Officer of IceCure Medical Ltd., which adds credibility to the information reported.

6. Implications for Investors:

• The reported 42% increase in sales may be a strong indicator of the company's growth trajectory and could positively impact investor sentiment.
• Investors should monitor follow-up reports or financial statements to assess the sustainability of this growth.

These points provide a succinct overview of the significant elements within the report, highlighting the company's performance and relevant disclosures.